

Monday 15th October	17:00 – 19.00 Registration opens, Drinks Reception	
Tuesday 16th October	Wednesday 17th October	Thursday 18th October
08:00 – 09:00 Registration continues	08:45 – 10:15 Session 5 : New Technologies in DMPK Chair: Mark Seymour	09:00 – 10:30 Session 10 : First In Human dose – regulatory and pharmacokinetic-pharmacodynamic considerations Chair: Rasmus J Löfmark
09:00 – 09:15 Chairpersons Opening Address		10:30 – 11:00 Coffee, Posters, Trade Exhibition
09:15 – 10:45 Session 1: Strategic collaborations: Pan European Industrial – Academic Partnerships Chair: Pawel Baranczewski	10:15 – 10:45 Coffee, Posters, Trade Exhibition	11:00 – 12:45 Session 11: The Application of DDI and PBPK in Regulatory Environment Chair: Anna Nordmark
10:45 – 11:15 Coffee, Posters, Trade Exhibition	10:45 – 12:30 Session 6: New Modalities – Part 1 Chair: Lars Weidolf	12:45 – 13:00 Closing Remarks
11:15 – 12:45 Session 2: Strategic approaches to tissue quantification Chair: Johan Bylund	12:30 – 13:30 Lunch, Posters, Trade Exhibition	13:00 – 14:00 Lunch
12:45 – 13:30 Lunch, Posters, Trade Exhibition	13:30 – 15:00 Session 7: New Modalities – Part 2 Chair: Jo Goodman	Delegates Depart
13:30 – 15:00 Session 3: Strategies for PKPD Modelling in Drug Discovery and Development Chair: Maria Kjellsson	15:00 – 15:30 Tea, Posters, Trade Exhibition	
15:00 – 15:30 Tea, Posters, Trade Exhibition	15:30 – 17:00 Session 8: Free Communications Chair: Graeme Scarfe	
15:30 – 16:30 Session 4: Student Poster Blitz/ Rosenön award Chairs: Rowan Stringer and Johanna Haglund	17:30 – 19:00 Session 9: Debate: Lipinski Rules are no longer relevant – Future drugs will need to be >5 kDa if they are to become “profitable” medicines Chair: Steve Hood	
16:30 – 17:30 Candlelight Keynote Speaker: Magnus Ingelman-Sundberg, Karolinska Institute Chair: Rasmus J. Löfmark	19:30 – 00:00 Drinks Reception, Conference Dinner	
17:30 – 19:30 Poster Session Trade Exhibition Drinks Reception		
19:30 Dinner (Own Arrangements)		

Monday 15th October

17:00 – 19:00:

Registration opens, **Drinks Reception**

Tuesday 16th October

08:00 – 09:00:

Registration continues

09:00 – 09:15:

Chairpersons Opening Address: Rowan Stringer (Novartis) and Johanna Haglund (MetaSafe – an Admescope company)

09:15 – 10:45:

Session 1: Strategic collaborations: Pan European Industrial – Academic Partnerships

Chair: Pawel Baranczewski, Uppsala University

Speakers:

- What have industrial/academic partnerships ever done for us?
Steve Hood, GSK
- Quantitative Systems Pharmacology is alive and well in the UK
James Yates, AstraZeneca
- Academic–Industrial Partnerships in Drug Discovery-Opportunity or Foe for Academic Research. Comments from Academic Point of View
Pawel Baranczewski, SciLifeLab DDD, ADMEoT/UDOPP, Uppsala University

10:45 – 11:15

Coffee, Posters, Trade Exhibition

11:15 – 12:45

Session 2: Strategic approaches to tissue quantification

Chair: Johan Bylund, Medivir

Speakers:

- To measure or not to measure? Tactics of tissue exposure assessment in drug research
Markus Fridén, AstraZeneca
- Determination of total tumor concentrations in xenograft models; experiences from Merck oncology projects
Carl Petersson, Merck KGaA
- Bioanalytical aspects of tissue quantification, experiences from a Medivir oncology project
Rodrigo Palma Villar, Medivir

12:45 – 13:30

Lunch, Posters, Trade Exhibition

13:30 – 15:00

Session 3: Strategies for PKPD Modelling in Drug Discovery and Development

Chair: Maria Kjellsson, Uppsala University

Speakers:

- Preclinical PK/PD modelling to support First-in-Man trial in oncology
Sheila Annie Peters, Merck KGaA
- Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure-target engagement
Rasmus J. Löfmark, AstraZeneca
- Using modelling & simulation throughout clinical drug development
Hanna Silber Baumann, F. Hoffmann-La Roche

15:00 – 15.30

Tea, Posters, Trade Exhibition

15:30 – 16:30

Session 4: Student Poster Blitz/ Rosenön award

Chair: Rowan Stringer, Novartis and Johanna Haglund, MetaSafe – an Admescope company

16:30 – 17:30

Candlelight Keynote Speaker

Chair: Rasmus Jansson Löfmark, AstraZeneca
Speaker: Magnus Ingelman-Sundberg, Karolinska Institute
Title: Drugs, genes and precision medicine, a tour from RFLP to NGS

17:30 – 19:30

Poster Session

19:30

Dinner (Own Arrangements)

Wednesday 17th October

08:45 – 10:15

Session 5: New Technologies in DMPK

Chair: Mark Seymour, Covance

Speakers:

- New Horizons in DMPK: The Next Wave of Automation
Scott Summerfield, GSK
- The Application of Ion Mobility Mass Spectrometry in DMPK Workflows
Richard Clayton, Covance
- Evaluation of transporter activity in stem cell derived renal models
Katarina Breitholtz, AstraZeneca

10:15 – 10:45

Coffee, Posters, Trade Exhibition

10:45 – 12:30

Session 6: New Modalities – Part 1

Chair: Lars Weidolf, AstraZeneca

Speakers:

- Chemical Analysis and Physicochemical Characterization of Peptides - a Chemistry Perspective
Tomas Leek, AstraZeneca
- ADME Characteristics of Semaglutide
Mette Lund Pedersen, NovoNordisk
- ¹⁴C-Labeling and Analysis Technologies to Enable Biologicals Drug Development
Wouter Vaes, TNO
- Highlights from the 1st workshop of the Peptide ADME Discussion Group
Jesper Kammersgaard Christensen, NovoNordisk

12:30 – 13:30

Lunch, Posters, Trade Exhibition

13:30 – 15:00

Session 7: New Modalities – Part 2

Chair: Joanne Goodman, MedImmune

Speakers:

- Bioanalytical Strategy for Locked Nucleic Acids (LNA) Therapeutics: Lessons Learned
Eric Bertran, F. Hoffmann-La Roche
- Bioanalysis and Biodistribution of Dendrimer Nanoparticles
Eric Gangl, AstraZeneca
- Discussion and Reflection Points from the EBF Focus Workshop on New Modalities: Science and Regulations Joining Hands
Philip Timmerman (on behalf of the European Bioanalytical Forum (EBF))

15:00 – 15:30

Tea, Posters, Trade Exhibition

15:30 – 17:00

Session 8: Free Communications

Chair: Graeme Scarfe, AstraZeneca

Speakers:

- Target-mediated drug disposition for small molecules: an overlooked area?
Robert van Waterschoot, F. Hoffmann-La Roche
- Application of in vitro parameters to predict non-linear absorption
Katie Haughan, AstraZeneca
- The rise of Deuterated Drugs
Ray Cooke, Pharmaron
- Development of a novel method to rapidly characterise uptake transporter activity in human hepatocytes in vitro: Applications and learnings
Oliver Light, UCB/ University of Bath

17:30 – 19:00

Session 9: Debate: Lipinski Rules are no longer relevant – Future drugs will need to be >5 kDa if they are to become “profitable” medicines

Ringmaster: Steve Hood, GSK

Speakers:

- Proposing – Kevin Brady (UCB) and Ben Krippendorf (F. Hoffmann-La Roche)
- Against – Dennis Smith (DMDG Fellow) and Barry Jones (AstraZeneca)

19:30 – 00:00

Drinks Reception, Conference Dinner

Thursday 18th October

09:00 – 10:30

Session 10: First In Human dose – regulatory and pharmacokinetic-pharmacodynamic considerations

Chair: Rasmus J. Löfmark, AstraZeneca

Speakers:

- The new EMA First in Human guideline
René Bouw, MPA
- IQ MABEL: First In Human MABEL approach and Survey Results
Sherri Dudal, F. Hoffmann-La Roche
- Integrated PKPD approach for the first-in-human dose selection of novel co-stimulatory cancer immunotherapies
Wouter Driessen, F. Hoffmann-La Roche

10:30 – 11:00

Coffee, Posters, Trade Exhibition

11:00 – 12:45

Session 11: The Application of DDI and PBPK in Regulatory Environment

Chair: Anna Nordmark, Scandinavian Development Services

Speakers:

- The use of Physiologically Based Pharmacokinetic Models for Regulatory Claims within EMA
Anna Nordmark, Scandinavian Development Services
- Physiologically based pharmacokinetic modelling current capabilities, case studies, and future opportunities: A Consortium Perspective
Venkatesh Pilla Reddy, AstraZeneca
- Comparison Between the US FDA, EMA and Japan PMDA In Vitro DDI Guidances: Are we Closer to Harmonization?
Brian Ogilvie, Sekisui XenoTech

12:45 – 13:00

Closing Remarks

13:00 – 14:00

Lunch and depart